OBJECTIVES: Patients with brain tumours have major disabilities and guarded prognosis but may benefit from inpatient rehabilitation.The objectives were to compare functional outcomes inpatients with glioblastoma multiforme(GBM), brain metastases and other brain tumours, and to determine predictors of survival. METHODS: Demographic, clinical,functional, and survival data were collected for 63 patients.Kaplan-Meier and Cox regression were used for survival analyses. RESULTS: Functional Independence Measure(FIM ) scores improved from admission to discharge for patients with GBM, brain metastases and other tumours. Estimated median survival was 141 days for brain metastases, 214 days for GBM and 439 days for other tumours. Low admission dexamethasone dose and high FIM gain predicted better survival in GBM. For brain metastases, high FIM gain, low dexamethasone dose and no organ metastases were positive prognostic factors. CONCLUSIONS: Patients with primary and metastatic brain tumours achieved functional gains after rehabilitation. High functional improvement is a significant predictor of longer survival in brain metastases and GBM. This study has implications for rehabilitation in the post-acute management of patients who have disabilities due to brain tumours.
OBJECTIVES:Patients with brain tumours have major disabilities and guarded prognosis but may benefit from inpatient rehabilitation.The objectives were to compare functional outcomes inpatients with glioblastoma multiforme(GBM), brain metastases and other brain tumours, and to determine predictors of survival. METHODS: Demographic, clinical,functional, and survival data were collected for 63 patients.Kaplan-Meier and Cox regression were used for survival analyses. RESULTS: Functional Independence Measure(FIM ) scores improved from admission to discharge for patients with GBM, brain metastases and other tumours. Estimated median survival was 141 days for brain metastases, 214 days for GBM and 439 days for other tumours. Low admission dexamethasone dose and high FIM gain predicted better survival in GBM. For brain metastases, high FIM gain, low dexamethasone dose and no organ metastases were positive prognostic factors. CONCLUSIONS:Patients with primary and metastatic brain tumours achieved functional gains after rehabilitation. High functional improvement is a significant predictor of longer survival in brain metastases and GBM. This study has implications for rehabilitation in the post-acute management of patients who have disabilities due to brain tumours.
Authors: Margaret Wrensch; James L Fisher; Judith A Schwartzbaum; Melissa Bondy; Mitchel Berger; Kenneth D Aldape Journal: Neurosurg Focus Date: 2005-11-15 Impact factor: 4.047
Authors: C Giannini; B W Scheithauer; A L Weaver; P C Burger; J M Kros; S Mork; M B Graeber; S Bauserman; J C Buckner; J Burton; R Riepe; H D Tazelaar; A G Nascimento; T Crotty; G L Keeney; P Pernicone; H Altermatt Journal: J Neuropathol Exp Neurol Date: 2001-03 Impact factor: 3.685
Authors: J F Lehmann; J A DeLisa; C G Warren; B J deLateur; P L Bryant; C G Nicholson Journal: Arch Phys Med Rehabil Date: 1978-09 Impact factor: 3.966
Authors: R Crevenna; M Schmidinger; M Keilani; M Nuhr; V Fialka-Moser; G Zettinig; M Quittan Journal: Support Care Cancer Date: 2002-11-01 Impact factor: 3.603
Authors: Lee W Jones; Allan H Friedman; Miranda J West; Stephanie K Mabe; Jennifer Fraser; William E Kraus; Henry S Friedman; Maura I Tresch; Nancy Major; David A Reardon Journal: Cancer Date: 2010-02-01 Impact factor: 6.860
Authors: Jacqueline M Mix; Carl V Granger; Michael J LaMonte; Paulette Niewczyk; Margaret A DiVita; Richard Goldstein; Jerome W Yates; Jo L Freudenheim Journal: Arch Phys Med Rehabil Date: 2017-02-01 Impact factor: 3.966
Authors: Benjamin W Corn; Meihua Wang; Sherry Fox; Jeffrey Michalski; James Purdy; Joseph Simpson; John Kresl; Walter J Curran; Aidnag Diaz; Minesh Mehta; Benjamin Movsas Journal: J Neurooncol Date: 2009-06-16 Impact factor: 4.130